2025-01-04 13:37:58,461 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:37:58,461 - INFO - Run 0:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will follow a structured approach, balancing historical patterns, current evidence, and potential risks.

### Step 1: Triage and Reference Relevant Predictions
- **Base Rate Analysis**: Historically, Clade I mpox has been endemic in Central Africa, with limited global spread. The 2022 outbreak involved Clade II, which spread globally but was contained relatively quickly. Clade I is more severe and transmissible, but its spread outside Africa has been minimal so far.
- **Current Predictions**: As of August 2024, no cases of Clade I have been confirmed in the US, but cases have been reported in Sweden and Pakistan, indicating potential for international spread.

### Step 2: Break the Problem into Sub-Problems
1. **Transmission Pathways**: Clade I is spreading in Africa and has reached Europe and Asia. The US has strong travel links with these regions, increasing the risk of importation.
2. **US Preparedness**: The US has robust surveillance systems, vaccination programs, and public health infrastructure, which could mitigate the spread.
3. **Timeframe**: The question focuses on a short timeframe (before October 1, 2024), limiting the window for potential spread.

### Step 3: Balance Inside and Outside Views
- **Outside View**: Based on historical patterns, the likelihood of Clade I spreading to the US in such a short timeframe is low. However, the recent cases in Sweden and Pakistan suggest increased risk.
- **Inside View**: The US is on high alert, with enhanced surveillance and vaccination efforts. This reduces the likelihood of undetected spread but does not eliminate it entirely.

### Step 4: Balance Under- and Overreacting to Evidence
- **Evidence for Higher Risk**: Clade I is more transmissible and severe, and its spread to Europe and Asia increases the risk of importation to the US.
- **Evidence for Lower Risk**: The US has strong public health measures, and no cases have been confirmed yet. The short timeframe limits the opportunity for widespread transmission.

### Step 5: Identify Clashing Causal Forces
- **Forces for Spread**: High transmissibility of Clade I, international travel, and potential gaps in surveillance.
- **Forces Against Spread**: Robust US public health infrastructure, vaccination programs, and heightened awareness.

### Step 6: Extrapolate Current Trends
- The trend shows Clade I spreading beyond Africa, but the US has not yet confirmed any cases. The trend suggests a moderate risk of importation.

### Step 7: Distinguish Degrees of Doubt
- The probability of Clade I reaching the US is uncertain but not negligible. The short timeframe adds uncertainty.

### Step 8: Balance Under- and Overconfidence
- While the risk is real, overconfidence in the US's ability to prevent spread could be misplaced. Conversely, underestimating the risk could lead to complacency.

### Step 9: Learn from Errors
- Historical outbreaks (e.g., COVID-19) show that initial underestimation of risk can lead to rapid spread. However, the US has learned from past experiences and is better prepared.

### Final Assessment
Considering the evidence, the likelihood of Clade I mpox being confirmed in the US before October 1, 2024, is moderate. The combination of heightened global spread, US preparedness, and the short timeframe leads to the following prediction:

**My Prediction: Between 30.00% and 50.00%, but 40.00% being the most likely. Probability: 40.00%.**

2025-01-04 13:38:17,971 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:38:17,971 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:38:17,972 - INFO - Run 1:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will follow a structured approach, balancing historical patterns, current evidence, and the unique features of the situation.

### Step 1: Triage and Reference Relevant Predictions
- As of now, there are no specific predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus regarding this exact question. However, the general consensus from health experts and organizations like the WHO and CDC suggests that the risk of Clade I mpox spreading to the US is low but not negligible.

### Step 2: Break the Problem into Tractable Sub-Problems
1. **Base Rate of Clade I Mpox Spread**: How often do new infectious disease strains spread from Africa to the US?
2. **Current Spread of Clade I Mpox**: What is the current geographic spread of Clade I mpox, and how likely is it to reach the US?
3. **US Preparedness and Surveillance**: How effective is the US in detecting and containing new infectious disease strains?
4. **Timeframe Consideration**: Given the timeframe (before October 1, 2024), how likely is it that Clade I mpox will be detected in the US?

### Step 3: Strike the Right Balance Between Inside and Outside Views
- **Outside View**: Historically, the spread of infectious diseases from Africa to the US has been relatively rare but not impossible. The 2022 mpox outbreak (Clade II) spread globally, including to the US, but Clade I has not yet been detected outside Africa except for one case in Sweden.
- **Inside View**: The current situation shows that Clade I is spreading rapidly in Africa, with cases confirmed in Sweden and Pakistan. The US has robust surveillance systems, but the risk of imported cases remains, especially given international travel.

### Step 4: Balance Under- and Overreacting to Evidence
- **Evidence for Higher Risk**: The WHO has declared a public health emergency, and Clade I has been detected outside Africa. The US has a high volume of international travel, which increases the risk of imported cases.
- **Evidence for Lower Risk**: The US has strong surveillance and containment measures, and the Jynneos vaccine is effective against both Clade I and II. No cases of Clade I have been reported in the US as of August 23, 2024.

### Step 5: Look for Clashing Causal Forces
- **Forces Increasing Risk**: High transmissibility of Clade I, international travel, and potential gaps in vaccination coverage.
- **Forces Decreasing Risk**: Effective US surveillance, vaccination campaigns, and public health preparedness.

### Step 6: Extrapolate Current Trends Linearly
- The current trend shows Clade I spreading beyond Africa, with cases in Sweden and Pakistan. If this trend continues, it is plausible that the US could see imported cases.

### Step 7: Distinguish Degrees of Doubt
- There is a moderate degree of uncertainty due to the unpredictable nature of infectious disease spread, but the evidence suggests a non-negligible risk.

### Step 8: Balance Under- and Overconfidence
- While the risk is not zero, it is also not extremely high. The US has strong systems in place to detect and contain outbreaks.

### Step 9: Learn from Errors and Avoid Hindsight Bias
- Historical outbreaks like the 2022 mpox outbreak show that the US can effectively manage such situations, but vigilance is required.

### Final Forecast
Considering the evidence and balancing the risks, I estimate that there is a moderate chance of Clade I mpox being confirmed in the US before October 1, 2024.

**My Prediction: Between 25.00% and 40.00%, but 32.50% being the most likely. Probability: 32.50%.**

2025-01-04 13:38:17,972 - INFO - Run 1:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will follow a structured approach, balancing historical patterns, current evidence, and the unique features of the situation.

### Step 1: Triage and Reference Relevant Predictions
- As of now, there are no specific predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus regarding this exact question. However, the general consensus from health experts and organizations like the WHO and CDC suggests that the risk of Clade I mpox spreading to the US is low but not negligible.

### Step 2: Break the Problem into Tractable Sub-Problems
1. **Base Rate of Clade I Mpox Spread**: How often do new infectious disease strains spread from Africa to the US?
2. **Current Spread of Clade I Mpox**: What is the current geographic spread of Clade I mpox, and how likely is it to reach the US?
3. **US Preparedness and Surveillance**: How effective is the US in detecting and containing new infectious disease strains?
4. **Timeframe Consideration**: Given the timeframe (before October 1, 2024), how likely is it that Clade I mpox will be detected in the US?

### Step 3: Strike the Right Balance Between Inside and Outside Views
- **Outside View**: Historically, the spread of infectious diseases from Africa to the US has been relatively rare but not impossible. The 2022 mpox outbreak (Clade II) spread globally, including to the US, but Clade I has not yet been detected outside Africa except for one case in Sweden.
- **Inside View**: The current situation shows that Clade I is spreading rapidly in Africa, with cases confirmed in Sweden and Pakistan. The US has robust surveillance systems, but the risk of imported cases remains, especially given international travel.

### Step 4: Balance Under- and Overreacting to Evidence
- **Evidence for Higher Risk**: The WHO has declared a public health emergency, and Clade I has been detected outside Africa. The US has a high volume of international travel, which increases the risk of imported cases.
- **Evidence for Lower Risk**: The US has strong surveillance and containment measures, and the Jynneos vaccine is effective against both Clade I and II. No cases of Clade I have been reported in the US as of August 23, 2024.

### Step 5: Look for Clashing Causal Forces
- **Forces Increasing Risk**: High transmissibility of Clade I, international travel, and potential gaps in vaccination coverage.
- **Forces Decreasing Risk**: Effective US surveillance, vaccination campaigns, and public health preparedness.

### Step 6: Extrapolate Current Trends Linearly
- The current trend shows Clade I spreading beyond Africa, with cases in Sweden and Pakistan. If this trend continues, it is plausible that the US could see imported cases.

### Step 7: Distinguish Degrees of Doubt
- There is a moderate degree of uncertainty due to the unpredictable nature of infectious disease spread, but the evidence suggests a non-negligible risk.

### Step 8: Balance Under- and Overconfidence
- While the risk is not zero, it is also not extremely high. The US has strong systems in place to detect and contain outbreaks.

### Step 9: Learn from Errors and Avoid Hindsight Bias
- Historical outbreaks like the 2022 mpox outbreak show that the US can effectively manage such situations, but vigilance is required.

### Final Forecast
Considering the evidence and balancing the risks, I estimate that there is a moderate chance of Clade I mpox being confirmed in the US before October 1, 2024.

**My Prediction: Between 25.00% and 40.00%, but 32.50% being the most likely. Probability: 32.50%.**

2025-01-04 13:38:43,059 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:38:43,059 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:38:43,059 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:38:43,060 - INFO - Run 2:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will break the problem into tractable sub-problems, balance historical patterns with current evidence, and weigh the risks of over- and under-adjusting to new information.

### Step 1: Base Rate Analysis (Outside View)
- **Historical Context**: Clade I mpox has been endemic in Central Africa, with sporadic outbreaks. The 2022 global outbreak involved Clade II, which spread primarily through close contact, particularly among men who have sex with men. Clade I is more severe and transmissible but has not yet established sustained transmission outside Africa.
- **Base Rate for Imported Cases**: Historically, infectious diseases like mpox have a low but non-zero probability of spreading internationally. For example, the 2022 Clade II outbreak saw rapid global spread, but Clade I has not yet shown similar behavior outside Africa.
- **Current Spread**: As of August 2024, Clade I has been confirmed in Sweden and Thailand, indicating international spread. However, no cases have been reported in the US.

### Step 2: Current Evidence (Inside View)
- **Travel and Surveillance**: The US has robust surveillance systems, including wastewater testing and diagnostic capacity, to detect mpox. Travelers from affected regions are being monitored, and health departments are on high alert.
- **Vaccination and Immunity**: The JYNNEOS vaccine, effective against both Clade I and II, has been widely distributed. However, vaccination rates are not universal, and some populations remain vulnerable.
- **Recent Developments**: The CDC has confirmed no Clade I cases in the US as of August 23, 2024. However, the detection of Clade I in Sweden and Thailand increases the likelihood of imported cases.

### Step 3: Balancing Evidence
- **Risk Factors**: The US has strong healthcare infrastructure and surveillance, reducing the likelihood of undetected spread. However, high travel volume and the presence of Clade I in Europe and Asia increase the risk of imported cases.
- **Mitigating Factors**: The JYNNEOS vaccine provides some protection, and public health measures are in place to contain outbreaks. The CDC has stated that the risk of Clade I spreading in the US is "very low."

### Step 4: Adjusting for Uncertainty
- **Timeframe**: The question asks about a short timeframe (before October 1, 2024), which limits the opportunity for widespread transmission.
- **Over- vs. Under-Adjusting**: While the detection of Clade I in Sweden and Thailand is concerning, it does not guarantee US cases. The US has not reported any Clade I cases despite heightened surveillance.

### Step 5: Final Probability Estimate
- **Base Rate Adjustment**: Given the historical rarity of Clade I spreading outside Africa, I start with a low base rate (e.g., 10%).
- **Current Evidence Adjustment**: The detection of Clade I in Sweden and Thailand increases the likelihood of US cases, but the robust US response and short timeframe mitigate this risk. I adjust the probability upward slightly to account for the increased risk of imported cases.
- **Final Estimate**: Balancing all factors, I estimate a 15-25% probability of Clade I mpox being confirmed in the US before October 1, 2024, with 20% being the most likely.

My Prediction: Between 15.00% and 25.00%, but 20.00% being the most likely. Probability: 20.00%.

2025-01-04 13:38:43,060 - INFO - Run 2:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will break the problem into tractable sub-problems, balance historical patterns with current evidence, and weigh the risks of over- and under-adjusting to new information.

### Step 1: Base Rate Analysis (Outside View)
- **Historical Context**: Clade I mpox has been endemic in Central Africa, with sporadic outbreaks. The 2022 global outbreak involved Clade II, which spread primarily through close contact, particularly among men who have sex with men. Clade I is more severe and transmissible but has not yet established sustained transmission outside Africa.
- **Base Rate for Imported Cases**: Historically, infectious diseases like mpox have a low but non-zero probability of spreading internationally. For example, the 2022 Clade II outbreak saw rapid global spread, but Clade I has not yet shown similar behavior outside Africa.
- **Current Spread**: As of August 2024, Clade I has been confirmed in Sweden and Thailand, indicating international spread. However, no cases have been reported in the US.

### Step 2: Current Evidence (Inside View)
- **Travel and Surveillance**: The US has robust surveillance systems, including wastewater testing and diagnostic capacity, to detect mpox. Travelers from affected regions are being monitored, and health departments are on high alert.
- **Vaccination and Immunity**: The JYNNEOS vaccine, effective against both Clade I and II, has been widely distributed. However, vaccination rates are not universal, and some populations remain vulnerable.
- **Recent Developments**: The CDC has confirmed no Clade I cases in the US as of August 23, 2024. However, the detection of Clade I in Sweden and Thailand increases the likelihood of imported cases.

### Step 3: Balancing Evidence
- **Risk Factors**: The US has strong healthcare infrastructure and surveillance, reducing the likelihood of undetected spread. However, high travel volume and the presence of Clade I in Europe and Asia increase the risk of imported cases.
- **Mitigating Factors**: The JYNNEOS vaccine provides some protection, and public health measures are in place to contain outbreaks. The CDC has stated that the risk of Clade I spreading in the US is "very low."

### Step 4: Adjusting for Uncertainty
- **Timeframe**: The question asks about a short timeframe (before October 1, 2024), which limits the opportunity for widespread transmission.
- **Over- vs. Under-Adjusting**: While the detection of Clade I in Sweden and Thailand is concerning, it does not guarantee US cases. The US has not reported any Clade I cases despite heightened surveillance.

### Step 5: Final Probability Estimate
- **Base Rate Adjustment**: Given the historical rarity of Clade I spreading outside Africa, I start with a low base rate (e.g., 10%).
- **Current Evidence Adjustment**: The detection of Clade I in Sweden and Thailand increases the likelihood of US cases, but the robust US response and short timeframe mitigate this risk. I adjust the probability upward slightly to account for the increased risk of imported cases.
- **Final Estimate**: Balancing all factors, I estimate a 15-25% probability of Clade I mpox being confirmed in the US before October 1, 2024, with 20% being the most likely.

My Prediction: Between 15.00% and 25.00%, but 20.00% being the most likely. Probability: 20.00%.

2025-01-04 13:38:43,060 - INFO - Run 2:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will break the problem into tractable sub-problems, balance historical patterns with current evidence, and weigh the risks of over- and under-adjusting to new information.

### Step 1: Base Rate Analysis (Outside View)
- **Historical Context**: Clade I mpox has been endemic in Central Africa, with sporadic outbreaks. The 2022 global outbreak involved Clade II, which spread primarily through close contact, particularly among men who have sex with men. Clade I is more severe and transmissible but has not yet established sustained transmission outside Africa.
- **Base Rate for Imported Cases**: Historically, infectious diseases like mpox have a low but non-zero probability of spreading internationally. For example, the 2022 Clade II outbreak saw rapid global spread, but Clade I has not yet shown similar behavior outside Africa.
- **Current Spread**: As of August 2024, Clade I has been confirmed in Sweden and Thailand, indicating international spread. However, no cases have been reported in the US.

### Step 2: Current Evidence (Inside View)
- **Travel and Surveillance**: The US has robust surveillance systems, including wastewater testing and diagnostic capacity, to detect mpox. Travelers from affected regions are being monitored, and health departments are on high alert.
- **Vaccination and Immunity**: The JYNNEOS vaccine, effective against both Clade I and II, has been widely distributed. However, vaccination rates are not universal, and some populations remain vulnerable.
- **Recent Developments**: The CDC has confirmed no Clade I cases in the US as of August 23, 2024. However, the detection of Clade I in Sweden and Thailand increases the likelihood of imported cases.

### Step 3: Balancing Evidence
- **Risk Factors**: The US has strong healthcare infrastructure and surveillance, reducing the likelihood of undetected spread. However, high travel volume and the presence of Clade I in Europe and Asia increase the risk of imported cases.
- **Mitigating Factors**: The JYNNEOS vaccine provides some protection, and public health measures are in place to contain outbreaks. The CDC has stated that the risk of Clade I spreading in the US is "very low."

### Step 4: Adjusting for Uncertainty
- **Timeframe**: The question asks about a short timeframe (before October 1, 2024), which limits the opportunity for widespread transmission.
- **Over- vs. Under-Adjusting**: While the detection of Clade I in Sweden and Thailand is concerning, it does not guarantee US cases. The US has not reported any Clade I cases despite heightened surveillance.

### Step 5: Final Probability Estimate
- **Base Rate Adjustment**: Given the historical rarity of Clade I spreading outside Africa, I start with a low base rate (e.g., 10%).
- **Current Evidence Adjustment**: The detection of Clade I in Sweden and Thailand increases the likelihood of US cases, but the robust US response and short timeframe mitigate this risk. I adjust the probability upward slightly to account for the increased risk of imported cases.
- **Final Estimate**: Balancing all factors, I estimate a 15-25% probability of Clade I mpox being confirmed in the US before October 1, 2024, with 20% being the most likely.

My Prediction: Between 15.00% and 25.00%, but 20.00% being the most likely. Probability: 20.00%.

2025-01-04 13:39:00,047 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:39:00,047 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:39:00,047 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:39:00,047 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:39:00,048 - INFO - Run 3:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will follow a structured approach, balancing historical patterns, current evidence, and the distinctive features of the situation.

### Step 1: Triage and Reference Relevant Predictions
- As of now, there are no widely available predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus specifically addressing this question. Therefore, I will rely on the available news articles and expert opinions.

### Step 2: Break the Problem into Sub-Problems
1. **Base Rate of Clade I Mpox Spread**: How often does Clade I mpox spread to new regions?
2. **Current Spread and Containment Efforts**: What is the current status of Clade I mpox spread globally and in the US?
3. **US Preparedness and Surveillance**: How prepared is the US to detect and contain Clade I mpox?
4. **Timeframe Consideration**: Is the timeframe (before October 1, 2024) sufficient for Clade I to reach and be confirmed in the US?

### Step 3: Strike the Right Balance Between Inside and Outside Views
- **Outside View**: Historically, Clade I mpox has been confined to Central and Eastern Africa. The recent spread to Sweden and Pakistan suggests that international travel can facilitate its spread. However, the US has robust surveillance and containment measures in place.
- **Inside View**: The US is on high alert for Clade I mpox, with enhanced surveillance and vaccination efforts. The JYNNEOS vaccine, while not perfect, provides some protection against Clade I.

### Step 4: Strike the Right Balance Between Under- and Overreacting to Evidence
- **Evidence for Higher Probability**: The recent spread to Sweden and Pakistan indicates that Clade I can spread internationally. The US has a high volume of international travel, increasing the risk of importation.
- **Evidence for Lower Probability**: The US has not yet confirmed any Clade I cases, and the JYNNEOS vaccine provides some level of protection. The CDC has stated that the risk of Clade I mpox coming to the US is "very low."

### Step 5: Look for the Clashing Causal Forces at Work
- **Forces Favoring Spread**: High international travel volume, potential for asymptomatic spread, and the more severe nature of Clade I.
- **Forces Favoring Containment**: Robust US surveillance, vaccination efforts, and public health infrastructure.

### Step 6: Extrapolate Current Trends Linearly
- The current trend shows Clade I spreading beyond Africa, with cases in Sweden and Pakistan. If this trend continues, it is plausible that Clade I could reach the US.

### Step 7: Strive to Distinguish Degrees of Doubt
- There is a moderate degree of uncertainty due to the limited number of cases outside Africa and the effectiveness of containment measures.

### Step 8: Strike the Right Balance Between Under- and Overconfidence
- Given the evidence, it is reasonable to be cautiously optimistic but not overly confident. The probability should reflect the balance between the potential for spread and the effectiveness of containment measures.

### Step 9: Look for Errors Behind Mistakes
- Potential errors include overestimating the effectiveness of containment measures or underestimating the potential for asymptomatic spread.

### Final Reasoning
- **Base Rate**: Historically, Clade I mpox has been confined to Africa, but recent cases in Sweden and Pakistan suggest it can spread internationally.
- **Current Spread**: Clade I has been confirmed in Sweden and Pakistan, indicating it can spread beyond Africa.
- **US Preparedness**: The US is on high alert, with enhanced surveillance and vaccination efforts. The CDC has stated the risk is "very low."
- **Timeframe**: The timeframe (before October 1, 2024) is relatively short, but given the recent spread to Sweden and Pakistan, it is plausible that Clade I could reach the US within this period.

Balancing these factors, I estimate that there is a moderate probability of Clade I mpox being confirmed in the US before October 1, 2024.

**My Prediction: Between 25.00% and 45.00%, but 35.00% being the most likely. Probability: 35.00%.**

2025-01-04 13:39:00,048 - INFO - Run 3:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will follow a structured approach, balancing historical patterns, current evidence, and the distinctive features of the situation.

### Step 1: Triage and Reference Relevant Predictions
- As of now, there are no widely available predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus specifically addressing this question. Therefore, I will rely on the available news articles and expert opinions.

### Step 2: Break the Problem into Sub-Problems
1. **Base Rate of Clade I Mpox Spread**: How often does Clade I mpox spread to new regions?
2. **Current Spread and Containment Efforts**: What is the current status of Clade I mpox spread globally and in the US?
3. **US Preparedness and Surveillance**: How prepared is the US to detect and contain Clade I mpox?
4. **Timeframe Consideration**: Is the timeframe (before October 1, 2024) sufficient for Clade I to reach and be confirmed in the US?

### Step 3: Strike the Right Balance Between Inside and Outside Views
- **Outside View**: Historically, Clade I mpox has been confined to Central and Eastern Africa. The recent spread to Sweden and Pakistan suggests that international travel can facilitate its spread. However, the US has robust surveillance and containment measures in place.
- **Inside View**: The US is on high alert for Clade I mpox, with enhanced surveillance and vaccination efforts. The JYNNEOS vaccine, while not perfect, provides some protection against Clade I.

### Step 4: Strike the Right Balance Between Under- and Overreacting to Evidence
- **Evidence for Higher Probability**: The recent spread to Sweden and Pakistan indicates that Clade I can spread internationally. The US has a high volume of international travel, increasing the risk of importation.
- **Evidence for Lower Probability**: The US has not yet confirmed any Clade I cases, and the JYNNEOS vaccine provides some level of protection. The CDC has stated that the risk of Clade I mpox coming to the US is "very low."

### Step 5: Look for the Clashing Causal Forces at Work
- **Forces Favoring Spread**: High international travel volume, potential for asymptomatic spread, and the more severe nature of Clade I.
- **Forces Favoring Containment**: Robust US surveillance, vaccination efforts, and public health infrastructure.

### Step 6: Extrapolate Current Trends Linearly
- The current trend shows Clade I spreading beyond Africa, with cases in Sweden and Pakistan. If this trend continues, it is plausible that Clade I could reach the US.

### Step 7: Strive to Distinguish Degrees of Doubt
- There is a moderate degree of uncertainty due to the limited number of cases outside Africa and the effectiveness of containment measures.

### Step 8: Strike the Right Balance Between Under- and Overconfidence
- Given the evidence, it is reasonable to be cautiously optimistic but not overly confident. The probability should reflect the balance between the potential for spread and the effectiveness of containment measures.

### Step 9: Look for Errors Behind Mistakes
- Potential errors include overestimating the effectiveness of containment measures or underestimating the potential for asymptomatic spread.

### Final Reasoning
- **Base Rate**: Historically, Clade I mpox has been confined to Africa, but recent cases in Sweden and Pakistan suggest it can spread internationally.
- **Current Spread**: Clade I has been confirmed in Sweden and Pakistan, indicating it can spread beyond Africa.
- **US Preparedness**: The US is on high alert, with enhanced surveillance and vaccination efforts. The CDC has stated the risk is "very low."
- **Timeframe**: The timeframe (before October 1, 2024) is relatively short, but given the recent spread to Sweden and Pakistan, it is plausible that Clade I could reach the US within this period.

Balancing these factors, I estimate that there is a moderate probability of Clade I mpox being confirmed in the US before October 1, 2024.

**My Prediction: Between 25.00% and 45.00%, but 35.00% being the most likely. Probability: 35.00%.**

2025-01-04 13:39:00,048 - INFO - Run 3:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will follow a structured approach, balancing historical patterns, current evidence, and the distinctive features of the situation.

### Step 1: Triage and Reference Relevant Predictions
- As of now, there are no widely available predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus specifically addressing this question. Therefore, I will rely on the available news articles and expert opinions.

### Step 2: Break the Problem into Sub-Problems
1. **Base Rate of Clade I Mpox Spread**: How often does Clade I mpox spread to new regions?
2. **Current Spread and Containment Efforts**: What is the current status of Clade I mpox spread globally and in the US?
3. **US Preparedness and Surveillance**: How prepared is the US to detect and contain Clade I mpox?
4. **Timeframe Consideration**: Is the timeframe (before October 1, 2024) sufficient for Clade I to reach and be confirmed in the US?

### Step 3: Strike the Right Balance Between Inside and Outside Views
- **Outside View**: Historically, Clade I mpox has been confined to Central and Eastern Africa. The recent spread to Sweden and Pakistan suggests that international travel can facilitate its spread. However, the US has robust surveillance and containment measures in place.
- **Inside View**: The US is on high alert for Clade I mpox, with enhanced surveillance and vaccination efforts. The JYNNEOS vaccine, while not perfect, provides some protection against Clade I.

### Step 4: Strike the Right Balance Between Under- and Overreacting to Evidence
- **Evidence for Higher Probability**: The recent spread to Sweden and Pakistan indicates that Clade I can spread internationally. The US has a high volume of international travel, increasing the risk of importation.
- **Evidence for Lower Probability**: The US has not yet confirmed any Clade I cases, and the JYNNEOS vaccine provides some level of protection. The CDC has stated that the risk of Clade I mpox coming to the US is "very low."

### Step 5: Look for the Clashing Causal Forces at Work
- **Forces Favoring Spread**: High international travel volume, potential for asymptomatic spread, and the more severe nature of Clade I.
- **Forces Favoring Containment**: Robust US surveillance, vaccination efforts, and public health infrastructure.

### Step 6: Extrapolate Current Trends Linearly
- The current trend shows Clade I spreading beyond Africa, with cases in Sweden and Pakistan. If this trend continues, it is plausible that Clade I could reach the US.

### Step 7: Strive to Distinguish Degrees of Doubt
- There is a moderate degree of uncertainty due to the limited number of cases outside Africa and the effectiveness of containment measures.

### Step 8: Strike the Right Balance Between Under- and Overconfidence
- Given the evidence, it is reasonable to be cautiously optimistic but not overly confident. The probability should reflect the balance between the potential for spread and the effectiveness of containment measures.

### Step 9: Look for Errors Behind Mistakes
- Potential errors include overestimating the effectiveness of containment measures or underestimating the potential for asymptomatic spread.

### Final Reasoning
- **Base Rate**: Historically, Clade I mpox has been confined to Africa, but recent cases in Sweden and Pakistan suggest it can spread internationally.
- **Current Spread**: Clade I has been confirmed in Sweden and Pakistan, indicating it can spread beyond Africa.
- **US Preparedness**: The US is on high alert, with enhanced surveillance and vaccination efforts. The CDC has stated the risk is "very low."
- **Timeframe**: The timeframe (before October 1, 2024) is relatively short, but given the recent spread to Sweden and Pakistan, it is plausible that Clade I could reach the US within this period.

Balancing these factors, I estimate that there is a moderate probability of Clade I mpox being confirmed in the US before October 1, 2024.

**My Prediction: Between 25.00% and 45.00%, but 35.00% being the most likely. Probability: 35.00%.**

2025-01-04 13:39:00,048 - INFO - Run 3:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will follow a structured approach, balancing historical patterns, current evidence, and the distinctive features of the situation.

### Step 1: Triage and Reference Relevant Predictions
- As of now, there are no widely available predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus specifically addressing this question. Therefore, I will rely on the available news articles and expert opinions.

### Step 2: Break the Problem into Sub-Problems
1. **Base Rate of Clade I Mpox Spread**: How often does Clade I mpox spread to new regions?
2. **Current Spread and Containment Efforts**: What is the current status of Clade I mpox spread globally and in the US?
3. **US Preparedness and Surveillance**: How prepared is the US to detect and contain Clade I mpox?
4. **Timeframe Consideration**: Is the timeframe (before October 1, 2024) sufficient for Clade I to reach and be confirmed in the US?

### Step 3: Strike the Right Balance Between Inside and Outside Views
- **Outside View**: Historically, Clade I mpox has been confined to Central and Eastern Africa. The recent spread to Sweden and Pakistan suggests that international travel can facilitate its spread. However, the US has robust surveillance and containment measures in place.
- **Inside View**: The US is on high alert for Clade I mpox, with enhanced surveillance and vaccination efforts. The JYNNEOS vaccine, while not perfect, provides some protection against Clade I.

### Step 4: Strike the Right Balance Between Under- and Overreacting to Evidence
- **Evidence for Higher Probability**: The recent spread to Sweden and Pakistan indicates that Clade I can spread internationally. The US has a high volume of international travel, increasing the risk of importation.
- **Evidence for Lower Probability**: The US has not yet confirmed any Clade I cases, and the JYNNEOS vaccine provides some level of protection. The CDC has stated that the risk of Clade I mpox coming to the US is "very low."

### Step 5: Look for the Clashing Causal Forces at Work
- **Forces Favoring Spread**: High international travel volume, potential for asymptomatic spread, and the more severe nature of Clade I.
- **Forces Favoring Containment**: Robust US surveillance, vaccination efforts, and public health infrastructure.

### Step 6: Extrapolate Current Trends Linearly
- The current trend shows Clade I spreading beyond Africa, with cases in Sweden and Pakistan. If this trend continues, it is plausible that Clade I could reach the US.

### Step 7: Strive to Distinguish Degrees of Doubt
- There is a moderate degree of uncertainty due to the limited number of cases outside Africa and the effectiveness of containment measures.

### Step 8: Strike the Right Balance Between Under- and Overconfidence
- Given the evidence, it is reasonable to be cautiously optimistic but not overly confident. The probability should reflect the balance between the potential for spread and the effectiveness of containment measures.

### Step 9: Look for Errors Behind Mistakes
- Potential errors include overestimating the effectiveness of containment measures or underestimating the potential for asymptomatic spread.

### Final Reasoning
- **Base Rate**: Historically, Clade I mpox has been confined to Africa, but recent cases in Sweden and Pakistan suggest it can spread internationally.
- **Current Spread**: Clade I has been confirmed in Sweden and Pakistan, indicating it can spread beyond Africa.
- **US Preparedness**: The US is on high alert, with enhanced surveillance and vaccination efforts. The CDC has stated the risk is "very low."
- **Timeframe**: The timeframe (before October 1, 2024) is relatively short, but given the recent spread to Sweden and Pakistan, it is plausible that Clade I could reach the US within this period.

Balancing these factors, I estimate that there is a moderate probability of Clade I mpox being confirmed in the US before October 1, 2024.

**My Prediction: Between 25.00% and 45.00%, but 35.00% being the most likely. Probability: 35.00%.**

2025-01-04 13:39:22,373 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:39:22,373 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:39:22,373 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:39:22,373 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:39:22,373 - INFO - Question: Will the US confirm Clade I mpox infections before October 1, 2024?
2025-01-04 13:39:22,375 - INFO - Run 4:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will follow a structured approach, balancing historical patterns, current evidence, and potential risks.

### Step 1: Triage and Reference Relevant Predictions
- There are no direct predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus on this specific question. However, the WHO has declared a public health emergency due to the spread of Clade I mpox in Africa, and the US has heightened surveillance and preparedness measures.

### Step 2: Break the Problem into Sub-Problems
1. **Base Rate of Clade I Spread to Non-Endemic Countries**: Historically, Clade I mpox has been confined to Central Africa. However, the recent case in Sweden (August 15, 2024) indicates potential for international spread.
2. **US Preparedness and Surveillance**: The US has robust surveillance systems, including wastewater testing and diagnostic capacity, and has distributed over 1 million doses of the Jynneos vaccine.
3. **Travel and Transmission Risk**: The US has significant travel links with Africa and Europe, increasing the risk of imported cases. However, the CDC has stated that the risk of Clade I mpox spreading in the US is "very low."
4. **Timeframe**: The question focuses on a short timeframe (August 23 to October 1, 2024), which limits the window for potential spread and detection.

### Step 3: Balance Inside and Outside Views
- **Outside View**: Historically, Clade I mpox has not spread widely outside Africa. The 2022 Clade II outbreak was contained in the US with effective vaccination and public health measures.
- **Inside View**: The recent case in Sweden and heightened global concern suggest a higher risk of international spread. However, the US has strong containment measures in place.

### Step 4: Balance Under- and Overreacting to Evidence
- The case in Sweden is concerning but isolated. The US has not reported any Clade I cases as of August 23, 2024, and the CDC has maintained a low-risk assessment.
- The Jynneos vaccine is expected to provide protection against Clade I, reducing the likelihood of widespread transmission.

### Step 5: Clashing Causal Forces
- **Forces Increasing Risk**: High travel volume, global interconnectedness, and the more severe nature of Clade I.
- **Forces Decreasing Risk**: Robust US surveillance, vaccination coverage, and public health infrastructure.

### Step 6: Extrapolate Current Trends Linearly
- The trend shows increasing cases in Africa and a single case in Europe. However, there is no evidence of sustained transmission outside Africa.

### Step 7: Degrees of Doubt
- The probability of Clade I mpox reaching the US is low but not zero. The short timeframe further limits the likelihood.

### Step 8: Balance Under- and Overconfidence
- While the risk is low, the potential consequences of a Clade I outbreak are severe, warranting cautious optimism.

### Step 9: Errors Behind Mistakes
- Overestimating the risk could lead to unnecessary panic, while underestimating it could result in inadequate preparedness. The current evidence suggests a balanced approach.

### Final Forecast
Given the low base rate of Clade I spread outside Africa, the US's strong public health measures, and the short timeframe, the probability of the US confirming Clade I mpox infections before October 1, 2024, is low but not negligible.

**My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.**

2025-01-04 13:39:22,375 - INFO - Run 4:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will follow a structured approach, balancing historical patterns, current evidence, and potential risks.

### Step 1: Triage and Reference Relevant Predictions
- There are no direct predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus on this specific question. However, the WHO has declared a public health emergency due to the spread of Clade I mpox in Africa, and the US has heightened surveillance and preparedness measures.

### Step 2: Break the Problem into Sub-Problems
1. **Base Rate of Clade I Spread to Non-Endemic Countries**: Historically, Clade I mpox has been confined to Central Africa. However, the recent case in Sweden (August 15, 2024) indicates potential for international spread.
2. **US Preparedness and Surveillance**: The US has robust surveillance systems, including wastewater testing and diagnostic capacity, and has distributed over 1 million doses of the Jynneos vaccine.
3. **Travel and Transmission Risk**: The US has significant travel links with Africa and Europe, increasing the risk of imported cases. However, the CDC has stated that the risk of Clade I mpox spreading in the US is "very low."
4. **Timeframe**: The question focuses on a short timeframe (August 23 to October 1, 2024), which limits the window for potential spread and detection.

### Step 3: Balance Inside and Outside Views
- **Outside View**: Historically, Clade I mpox has not spread widely outside Africa. The 2022 Clade II outbreak was contained in the US with effective vaccination and public health measures.
- **Inside View**: The recent case in Sweden and heightened global concern suggest a higher risk of international spread. However, the US has strong containment measures in place.

### Step 4: Balance Under- and Overreacting to Evidence
- The case in Sweden is concerning but isolated. The US has not reported any Clade I cases as of August 23, 2024, and the CDC has maintained a low-risk assessment.
- The Jynneos vaccine is expected to provide protection against Clade I, reducing the likelihood of widespread transmission.

### Step 5: Clashing Causal Forces
- **Forces Increasing Risk**: High travel volume, global interconnectedness, and the more severe nature of Clade I.
- **Forces Decreasing Risk**: Robust US surveillance, vaccination coverage, and public health infrastructure.

### Step 6: Extrapolate Current Trends Linearly
- The trend shows increasing cases in Africa and a single case in Europe. However, there is no evidence of sustained transmission outside Africa.

### Step 7: Degrees of Doubt
- The probability of Clade I mpox reaching the US is low but not zero. The short timeframe further limits the likelihood.

### Step 8: Balance Under- and Overconfidence
- While the risk is low, the potential consequences of a Clade I outbreak are severe, warranting cautious optimism.

### Step 9: Errors Behind Mistakes
- Overestimating the risk could lead to unnecessary panic, while underestimating it could result in inadequate preparedness. The current evidence suggests a balanced approach.

### Final Forecast
Given the low base rate of Clade I spread outside Africa, the US's strong public health measures, and the short timeframe, the probability of the US confirming Clade I mpox infections before October 1, 2024, is low but not negligible.

**My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.**

2025-01-04 13:39:22,375 - INFO - Run 4:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will follow a structured approach, balancing historical patterns, current evidence, and potential risks.

### Step 1: Triage and Reference Relevant Predictions
- There are no direct predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus on this specific question. However, the WHO has declared a public health emergency due to the spread of Clade I mpox in Africa, and the US has heightened surveillance and preparedness measures.

### Step 2: Break the Problem into Sub-Problems
1. **Base Rate of Clade I Spread to Non-Endemic Countries**: Historically, Clade I mpox has been confined to Central Africa. However, the recent case in Sweden (August 15, 2024) indicates potential for international spread.
2. **US Preparedness and Surveillance**: The US has robust surveillance systems, including wastewater testing and diagnostic capacity, and has distributed over 1 million doses of the Jynneos vaccine.
3. **Travel and Transmission Risk**: The US has significant travel links with Africa and Europe, increasing the risk of imported cases. However, the CDC has stated that the risk of Clade I mpox spreading in the US is "very low."
4. **Timeframe**: The question focuses on a short timeframe (August 23 to October 1, 2024), which limits the window for potential spread and detection.

### Step 3: Balance Inside and Outside Views
- **Outside View**: Historically, Clade I mpox has not spread widely outside Africa. The 2022 Clade II outbreak was contained in the US with effective vaccination and public health measures.
- **Inside View**: The recent case in Sweden and heightened global concern suggest a higher risk of international spread. However, the US has strong containment measures in place.

### Step 4: Balance Under- and Overreacting to Evidence
- The case in Sweden is concerning but isolated. The US has not reported any Clade I cases as of August 23, 2024, and the CDC has maintained a low-risk assessment.
- The Jynneos vaccine is expected to provide protection against Clade I, reducing the likelihood of widespread transmission.

### Step 5: Clashing Causal Forces
- **Forces Increasing Risk**: High travel volume, global interconnectedness, and the more severe nature of Clade I.
- **Forces Decreasing Risk**: Robust US surveillance, vaccination coverage, and public health infrastructure.

### Step 6: Extrapolate Current Trends Linearly
- The trend shows increasing cases in Africa and a single case in Europe. However, there is no evidence of sustained transmission outside Africa.

### Step 7: Degrees of Doubt
- The probability of Clade I mpox reaching the US is low but not zero. The short timeframe further limits the likelihood.

### Step 8: Balance Under- and Overconfidence
- While the risk is low, the potential consequences of a Clade I outbreak are severe, warranting cautious optimism.

### Step 9: Errors Behind Mistakes
- Overestimating the risk could lead to unnecessary panic, while underestimating it could result in inadequate preparedness. The current evidence suggests a balanced approach.

### Final Forecast
Given the low base rate of Clade I spread outside Africa, the US's strong public health measures, and the short timeframe, the probability of the US confirming Clade I mpox infections before October 1, 2024, is low but not negligible.

**My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.**

2025-01-04 13:39:22,375 - INFO - Run 4:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will follow a structured approach, balancing historical patterns, current evidence, and potential risks.

### Step 1: Triage and Reference Relevant Predictions
- There are no direct predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus on this specific question. However, the WHO has declared a public health emergency due to the spread of Clade I mpox in Africa, and the US has heightened surveillance and preparedness measures.

### Step 2: Break the Problem into Sub-Problems
1. **Base Rate of Clade I Spread to Non-Endemic Countries**: Historically, Clade I mpox has been confined to Central Africa. However, the recent case in Sweden (August 15, 2024) indicates potential for international spread.
2. **US Preparedness and Surveillance**: The US has robust surveillance systems, including wastewater testing and diagnostic capacity, and has distributed over 1 million doses of the Jynneos vaccine.
3. **Travel and Transmission Risk**: The US has significant travel links with Africa and Europe, increasing the risk of imported cases. However, the CDC has stated that the risk of Clade I mpox spreading in the US is "very low."
4. **Timeframe**: The question focuses on a short timeframe (August 23 to October 1, 2024), which limits the window for potential spread and detection.

### Step 3: Balance Inside and Outside Views
- **Outside View**: Historically, Clade I mpox has not spread widely outside Africa. The 2022 Clade II outbreak was contained in the US with effective vaccination and public health measures.
- **Inside View**: The recent case in Sweden and heightened global concern suggest a higher risk of international spread. However, the US has strong containment measures in place.

### Step 4: Balance Under- and Overreacting to Evidence
- The case in Sweden is concerning but isolated. The US has not reported any Clade I cases as of August 23, 2024, and the CDC has maintained a low-risk assessment.
- The Jynneos vaccine is expected to provide protection against Clade I, reducing the likelihood of widespread transmission.

### Step 5: Clashing Causal Forces
- **Forces Increasing Risk**: High travel volume, global interconnectedness, and the more severe nature of Clade I.
- **Forces Decreasing Risk**: Robust US surveillance, vaccination coverage, and public health infrastructure.

### Step 6: Extrapolate Current Trends Linearly
- The trend shows increasing cases in Africa and a single case in Europe. However, there is no evidence of sustained transmission outside Africa.

### Step 7: Degrees of Doubt
- The probability of Clade I mpox reaching the US is low but not zero. The short timeframe further limits the likelihood.

### Step 8: Balance Under- and Overconfidence
- While the risk is low, the potential consequences of a Clade I outbreak are severe, warranting cautious optimism.

### Step 9: Errors Behind Mistakes
- Overestimating the risk could lead to unnecessary panic, while underestimating it could result in inadequate preparedness. The current evidence suggests a balanced approach.

### Final Forecast
Given the low base rate of Clade I spread outside Africa, the US's strong public health measures, and the short timeframe, the probability of the US confirming Clade I mpox infections before October 1, 2024, is low but not negligible.

**My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.**

2025-01-04 13:39:22,375 - INFO - Run 4:
To forecast whether the US will confirm Clade I mpox infections before October 1, 2024, I will follow a structured approach, balancing historical patterns, current evidence, and potential risks.

### Step 1: Triage and Reference Relevant Predictions
- There are no direct predictions from platforms like FiveThirtyEight, Polymarket, or Metaculus on this specific question. However, the WHO has declared a public health emergency due to the spread of Clade I mpox in Africa, and the US has heightened surveillance and preparedness measures.

### Step 2: Break the Problem into Sub-Problems
1. **Base Rate of Clade I Spread to Non-Endemic Countries**: Historically, Clade I mpox has been confined to Central Africa. However, the recent case in Sweden (August 15, 2024) indicates potential for international spread.
2. **US Preparedness and Surveillance**: The US has robust surveillance systems, including wastewater testing and diagnostic capacity, and has distributed over 1 million doses of the Jynneos vaccine.
3. **Travel and Transmission Risk**: The US has significant travel links with Africa and Europe, increasing the risk of imported cases. However, the CDC has stated that the risk of Clade I mpox spreading in the US is "very low."
4. **Timeframe**: The question focuses on a short timeframe (August 23 to October 1, 2024), which limits the window for potential spread and detection.

### Step 3: Balance Inside and Outside Views
- **Outside View**: Historically, Clade I mpox has not spread widely outside Africa. The 2022 Clade II outbreak was contained in the US with effective vaccination and public health measures.
- **Inside View**: The recent case in Sweden and heightened global concern suggest a higher risk of international spread. However, the US has strong containment measures in place.

### Step 4: Balance Under- and Overreacting to Evidence
- The case in Sweden is concerning but isolated. The US has not reported any Clade I cases as of August 23, 2024, and the CDC has maintained a low-risk assessment.
- The Jynneos vaccine is expected to provide protection against Clade I, reducing the likelihood of widespread transmission.

### Step 5: Clashing Causal Forces
- **Forces Increasing Risk**: High travel volume, global interconnectedness, and the more severe nature of Clade I.
- **Forces Decreasing Risk**: Robust US surveillance, vaccination coverage, and public health infrastructure.

### Step 6: Extrapolate Current Trends Linearly
- The trend shows increasing cases in Africa and a single case in Europe. However, there is no evidence of sustained transmission outside Africa.

### Step 7: Degrees of Doubt
- The probability of Clade I mpox reaching the US is low but not zero. The short timeframe further limits the likelihood.

### Step 8: Balance Under- and Overconfidence
- While the risk is low, the potential consequences of a Clade I outbreak are severe, warranting cautious optimism.

### Step 9: Errors Behind Mistakes
- Overestimating the risk could lead to unnecessary panic, while underestimating it could result in inadequate preparedness. The current evidence suggests a balanced approach.

### Final Forecast
Given the low base rate of Clade I spread outside Africa, the US's strong public health measures, and the short timeframe, the probability of the US confirming Clade I mpox infections before October 1, 2024, is low but not negligible.

**My Prediction: Between 5.00% and 15.00%, but 10.00% being the most likely. Probability: 10.00%.**

